In July 2023, the U.S. Federal Drug Administration (FDA) approved Leqembi, for the treatment of Alzheimer’s disease. Leqembi is the second of a new category of medications approved for Alzheimer’s disease that targets the fundamental pathophysiology of the disease and represent an important advancement in the ongoing fight to effectively treat Alzheimer’s disease.
Leqembi is delivered via infusion therapy every two weeks. This means the medicine is administered directly into the bloodstream. It works by reducing the amyloid beta plaque, a marker in patients with mild cognitive impairment or mild dementia stage of the disease.
For patients seeking this new therapy, Infusion for Health provides a comfortable, relaxing environment to receive Leqembi infusion treatments. Our dedicated team of medical professionals understands the struggles and challenges Alzheimer’s patients and their families face. It’s our mission to not only provide quality care, but to pamper our patients as they receive their infusion therapy sessions. Importantly we also work directly with our patients and their families to handle all insurance coverage, including for patients eligible for Medicare coverage.
Alzheimer’s disease is a progressive disease that causes memory loss over time. Common early signs of Alzheimer’s include:
Right now, scientists don’t know what causes Alzheimer’s disease. However, they have identified two types of problems that are common in Alzheimer’s patients:
These two factors work together to damage the brain. As tangles and plaques build up in the brain, healthy cells get damaged and die. This causes the brain to shrink and deteriorate over time, resulting in the symptoms of Alzheimer’s.
While the actual cause of Alzheimer’s is unknown, there are some factors which seem to be associated with increased risk:
Leqembi was approved on the FDA’s Accelerated Approval pathway, meaning there was enough evidence during clinical trials to show that the drug met its primary goals: to show a statistically significant reduction in brain amyloid plaque. Patients in the clinical trial delayed cognitive decline by 5.3 months compared to placebo after 18 months of treatment.
Medicare will cover treatment for all patients with confirmed mild cognitive impairment or mild dementia with confirmed amyloid plaques. Other insurance plans may also provide coverage for Leqembi. At Infusion for Health, we take pride in helping our patients to navigate the best coverage option for care. Learn more about how Infusion for Health helps our patients afford care.
Leqembi is approved for those in the early stages of Alzheimer’s progression. By receiving treatment, those who show signs of the disease may have more quality time with their families, stay independent longer, and enjoy a higher quality of life.
At Infusion for Health, your comfort and care are our priority. It’s our mission to provide a comfortable, safe environment during infusion therapy sessions, whether you are receiving Leqembi for Alzheimer’s or another infusion treatment. Every one of our private suites comes equipped with a comfortable armchair, warm blankets, snacks, and a television with online access to make each session an enjoyable experience. Our private suites make it easy for family member or caregivers to accompany patients who are receiving therapy
If you or someone you love is considering infusion therapy for Alzheimer’s, we’re here to help. Learn more about planning your visit and receiving your treatment from Infusion for Health.